Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium, Inc. (NASDAQ: EQ) presented positive results from its EQUATE study at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. The study analyzed the use of itolizumab combined with systemic corticosteroids in treating acute graft-versus-host disease (aGVHD). The findings showed significant clinical responses and improved progression-free survival rates over one year. Itolizumab demonstrated a favorable safety profile and may reduce corticosteroid usage by 99% within six months. Following this data, the pivotal Phase 3 EQUATOR study of itolizumab is underway, targeting first-line treatment of aGVHD, a condition with no approved first-line therapies.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
